Det primære effektendepunkt i hvert studie var den andel af patienterne, hvis sidste tre månedlige serumurinsyreniveauer var < 357 µmol/ L (6, 0 mg/ dL).
The primary efficacy endpoint in each study was the proportion of patients whose last 3 monthly serum uric acid levels were < 6.0 mg/ dl (357 µmol/ l).